Eton Pharmaceuticals, Inc.
Company Stats
- Market Cap
- $1.5B
- as of Sep 30, 2026
- Shares Outstanding
- 28.6M
- Free Float
- 72.4%
Income Statement
- Revenue
- $80.0M
- Operating Income
- -$844,000
- Net Income
- -$4.6M
- EBITDA
- -$803,000
- Revenue Growth, 3Y
- 55.5%
- FCF Margin, 3Y Avg
- 12.2%
- FCF Margin, Worst Year
- 2.4%
Cash Flow
- Free Cash Flow
- $10.2M
- FCF Yield
- 0.7%
- Owner FCF Yield
- 0.3%
Balance Sheet
- Cash & Equivalents
- $25.9M
Returns & Capital
- SBC, 3Y Avg
- $3.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $80.0M | $10.2M | 12.7% |
| FY2024 | $39.0M | $943,000 | 2.4% |
| FY2023 | $31.6M | $6.8M | 21.5% |
| FY2022 | $21.3M | $4.8M | 22.5% |
| FY2021 | $21.8M | -$4.7M | -21.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 18, 2026
Weekly Deals
Micro-Cap Deals Roundup for Week of Oct. 12, 2026
October 14, 2026
Deals
Eton to License Libervant Buccal Film for U.S. Launch
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 5, 2026
Deals
Eton Pharmaceuticals to Acquire U.S. Rights to ASN-001 From Auson
Micro-Cap Deals Roundup for Week of Oct. 12, 2026
October 14, 2026
Deals
Eton to License Libervant Buccal Film for U.S. Launch
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 5, 2026
Deals
Eton Pharmaceuticals to Acquire U.S. Rights to ASN-001 From Auson